---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-030518"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:09:59.319708+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance

## Summary
- Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).
- Amgen discontinuing participation; Kyowa Kirin to assume all development, manufacturing, and commercialization worldwide.
- Transition effective upon satisfaction of HSR Act waiting period and other regulatory conditions.
- If conditions not met by April 1, 2026 (extendable to June 1, 2026 due to government shutdown), Amgen may terminate and wind down.
- Amgen and Kyowa Kirin also entering a Transition Agreement to facilitate transfer of activities.

## SEC filing metadata
- accession: 0001193125-26-030518
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312526030518/0001193125-26-030518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312526030518/d72347d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-030518
- JSON: https://secwatch.observer/filing/0001193125-26-030518.json
- Plain text: https://secwatch.observer/filing/0001193125-26-030518.txt

## Key facts
- Material Agreements
  AMGEN INC terminated License and Collaboration Agreement with Kyowa Kirin Co., Ltd. (effective 2026-01-30).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Kyowa Kirin Co., Ltd.
  - Effective: 2026-01-30
  source text: On January 30, 2026, Amgen Inc. (the “ Company ”) entered into a Termination Agreement (the “ Termination Agreement ”) with Kyowa Kirin Co., Ltd. (“ Kyowa Kirin ”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “ License and Collaboration Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312526030518/0001193125-26-030518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.